Cargando…

Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a highly heterogeneous tumor, resulting a challenge of developing target therapeutics. Not long ago, immune checkpoint blockade regimens combine with tyrosin kinase inhibitors have evolved frontline options in metastatic RCC, which implies arriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Zhuangyao, Yao, Haohua, Wei, Jinhuan, Feng, Zihao, Chen, Wei, Luo, Junhang, Chen, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100830/
https://www.ncbi.nlm.nih.gov/pubmed/33968649
http://dx.doi.org/10.21037/tau-20-1348
_version_ 1783688862596333568
author Liao, Zhuangyao
Yao, Haohua
Wei, Jinhuan
Feng, Zihao
Chen, Wei
Luo, Junhang
Chen, Xu
author_facet Liao, Zhuangyao
Yao, Haohua
Wei, Jinhuan
Feng, Zihao
Chen, Wei
Luo, Junhang
Chen, Xu
author_sort Liao, Zhuangyao
collection PubMed
description BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a highly heterogeneous tumor, resulting a challenge of developing target therapeutics. Not long ago, immune checkpoint blockade regimens combine with tyrosin kinase inhibitors have evolved frontline options in metastatic RCC, which implies arrival of the era of tumor immunotherapy. Studies have demonstrated immune-related genes (IRGs) could characterize tumor milieu and related to patient survival. Nevertheless, the clinical significance of classifier depending on IRGs in ccRCC has not been well established. METHODS: The R package limma, univariate and LASSO cox regression analysis were used to screen the prognostic related IRGs from TCGA database. Multivariate cox regression was utilized to establish a risk prediction model for candidate genes. Quantitative real-time PCR was used to confirm the expression of candidates in clinical samples from our institution. CIBERSORT algorithm and correlation analysis were applied to explore tumor-infiltrating immune cells signature between different risk groups. A clinical nomogram was also developed to predict OS by using the rms R package based on the risk prediction model and other independent risk factors. The ICGC data was used for external validation of either gene risk model or nomogram. RESULTS: We identified 382 differentially expressed immune related genes. Four unique prognostic IRGs (CRABP2, LTB4R, PTGER1 and TEK) were finally affirmed to associate with tumor survival independently and utilized to establish the risk score model. All candidates’ expression was successfully laboratory confirmed by q-PCR. CIBERSORT analysis implied patients in unfavorable-risk group with high CD8 T cell, regulatory T cell and NK cell infiltration, as well as high expression of PD-1, CTLA4, TNFRSF9, TIGIT and LAG3. A nomogram combined IRGs risk score with age, gender, TNM stage, Fuhrman grade, necrosis was further generated to predict of 3- and 5-year OS, which exhibited superior discriminative power (AUCs were 0.811 and 0.795). CONCLUSIONS: Our study established and validated a survival prognostic model system based on 4 unique immune related genes in ccRCC, which expands knowledge in tumor immune status and provide a potent prediction tool in future.
format Online
Article
Text
id pubmed-8100830
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-81008302021-05-07 Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma Liao, Zhuangyao Yao, Haohua Wei, Jinhuan Feng, Zihao Chen, Wei Luo, Junhang Chen, Xu Transl Androl Urol Original Article BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a highly heterogeneous tumor, resulting a challenge of developing target therapeutics. Not long ago, immune checkpoint blockade regimens combine with tyrosin kinase inhibitors have evolved frontline options in metastatic RCC, which implies arrival of the era of tumor immunotherapy. Studies have demonstrated immune-related genes (IRGs) could characterize tumor milieu and related to patient survival. Nevertheless, the clinical significance of classifier depending on IRGs in ccRCC has not been well established. METHODS: The R package limma, univariate and LASSO cox regression analysis were used to screen the prognostic related IRGs from TCGA database. Multivariate cox regression was utilized to establish a risk prediction model for candidate genes. Quantitative real-time PCR was used to confirm the expression of candidates in clinical samples from our institution. CIBERSORT algorithm and correlation analysis were applied to explore tumor-infiltrating immune cells signature between different risk groups. A clinical nomogram was also developed to predict OS by using the rms R package based on the risk prediction model and other independent risk factors. The ICGC data was used for external validation of either gene risk model or nomogram. RESULTS: We identified 382 differentially expressed immune related genes. Four unique prognostic IRGs (CRABP2, LTB4R, PTGER1 and TEK) were finally affirmed to associate with tumor survival independently and utilized to establish the risk score model. All candidates’ expression was successfully laboratory confirmed by q-PCR. CIBERSORT analysis implied patients in unfavorable-risk group with high CD8 T cell, regulatory T cell and NK cell infiltration, as well as high expression of PD-1, CTLA4, TNFRSF9, TIGIT and LAG3. A nomogram combined IRGs risk score with age, gender, TNM stage, Fuhrman grade, necrosis was further generated to predict of 3- and 5-year OS, which exhibited superior discriminative power (AUCs were 0.811 and 0.795). CONCLUSIONS: Our study established and validated a survival prognostic model system based on 4 unique immune related genes in ccRCC, which expands knowledge in tumor immune status and provide a potent prediction tool in future. AME Publishing Company 2021-04 /pmc/articles/PMC8100830/ /pubmed/33968649 http://dx.doi.org/10.21037/tau-20-1348 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Liao, Zhuangyao
Yao, Haohua
Wei, Jinhuan
Feng, Zihao
Chen, Wei
Luo, Junhang
Chen, Xu
Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
title Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
title_full Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
title_fullStr Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
title_full_unstemmed Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
title_short Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
title_sort development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100830/
https://www.ncbi.nlm.nih.gov/pubmed/33968649
http://dx.doi.org/10.21037/tau-20-1348
work_keys_str_mv AT liaozhuangyao developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma
AT yaohaohua developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma
AT weijinhuan developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma
AT fengzihao developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma
AT chenwei developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma
AT luojunhang developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma
AT chenxu developmentandvalidationoftheprognosticvalueoftheimmunerelatedgenesinclearcellrenalcellcarcinoma